Forte Medical case study within Imperial College Innovation paper

Commissioned by Lord Sainsbury and authored by Professor James Moore and Yunus Kutlu, Imperial College has published a report on innovation adoption in the UK and wh

at prevents successful adoption of impactful innovation. Forte Medical features as the only case study and outlines issues with silo systems, a disconnect between procurement and fincance all topped off with vested interests from labs and leadership.

The Peezy Midstream case study outlines how adoption of preventative devices and practice are resisted, leading to missed opportunities for improved patient health, prompt diagnoses, prevention and huge cost savings across the patient pathway.

Read all about it here. – see Page 29 and Appendix 2

US Partnership Deal With Owen Mumford Announced

The partnership between Forte Medical and Owen Mumford USA was launched today at the OCTANe Medical Innovation Technology Forum (MTIF) at Newport Beach, CA 28-29 October 2019. 

Introducing Peezy Midstream to the USA has long been an ambition of Forte Medical. Our disruptive and innovative MedTech called for a partner with experience, knowledge and a savvy mindset. We found that partner in Atlanta-based Owen Mumford USA whose reach covers the USA and Canada and is managed by Travis Shaw.

Owen Mumford has been at the forefront of medical device innovation for over 65 years, creating solutions that improve the delivery of healthcare and home health treatments for people around the world. Their products span devices that make blood testing more comfortable to solutions that make it easier to administer life-saving medication.

Owen Mumford’s experience in medical devices began in the 1950s when founders Ivan Owen and John Mumford established the company. The company have direct sales offices and a network of distribution partners serving customers in over 60 countries, and employ over 800 people across the Americas, Europe and Asia.  

“Owen Mumford USA is delighted to partner Forte Medical in North America and Canada,” says Travis Shaw. “Our team looks forward to expanding our mutual synergies. Research indicates that Peezy Midstream can add significant clinical and cost value to healthcare providers, a true win-win for all parties.”
 
Thanks to the Greater Irvine Chamber of Commerce for making this possible.

Antibiotics and urinary tract infections

Antibiotics, better tests, UTI: Guardian publishes Forte response

A rise in persistent UTIs could be linked to antibiotic crackdown appeared in The Guardian on Saturday 5th October. As usual, no-one mentioned accurate basic specimen collection, which can lead to unwarranted specimen quality variation, failed analysis and less-than-targeted prescribing. Giovanna Forte had something to say. Click here to read her published letter.

urine infection testing

New study concludes midstream urine optimises point of care accuracy

An interesting study published in the Scandinavian Journal of Primary Health Care which concludes: “MSU samples should be used in general practice for optimal accuracy of POC tests.”

Click here for more information Sampling of urine for diagnosing urinary tract infection in general practice – First-void or mid-stream urine?

Hoelmkjaer Pernille, Bjerrum Lars, Mäkelä Marjukka, Siersma Volkert & Holm Anne (2019): Sampling of urine for diagnosing urinary tract infection in general practice – First-void or mid-stream urine?, Scandinavian Journal of Primary Health Care, DOI: 10.1080/02813432.2019.1568708

Comment: The Basic Diagnostic Failure That Affects 1 in 3 Women

Its time to reignite our NHS! Now our beloved health system has been blessed with new funding, we can furnish every hospital and GP practice with the latest digital technology and AI. We can burnish the reputations of our healthcare leaders because they have modernized patient care. 

It seems it is so much easier to spend new money, than it is to fix a failing system. Yet while this exciting digital revolution takes place, the Department of Health and NHS continue to fail 15m patients every year, whilst flushing £1.2bn of public funds down the loo. This is more than a shame; it’s a scandal.

There is one basic diagnostic process which is not as sexy as glittering new tech. It doesn’t excite our healthcare commentators. It will not invest our clinical leadership with shiny accolades that add kudos to reputation. It will not be covered by the media because it’s a waste product that no one really likes to talk about. Yet this waste product carries as much, if not more diagnostic clues to our health as its counterpart, blood. We need to talk about urine.

“If you don’t make the effort to collect the urine specimen properly, all the clever stuff you do later is pretty pointless. It’s a case of rubbish in, rubbish out,” says a Senior Microbiologist at Barts’ Heath NHS Trust. “The need for change is likely to be politically driven, rather than scientifically.”  The science is evident, the political will is not.

The lack of any protocol for urine collection is causing persistent, widespread and expensive diagnostic failure that starts in the GP surgery. For unreliable frontline diagnoses lead to critical conditions, hospital admissions, and expensive, complex treatment, not to mention the millions of patients who continue to suffer. This is not the fault of our hardworking and overstretched GPs and frontline nursing staff.  It is our healthcare leaders who persistently overlook the need to make urine analysis and treatment right-first-time.

Take urinary tract infection (UTI), a condition largely suffered by women. The last relevant data to come out of the NHS Unplanned Admissions Committee cites untreated UTI as the cause of 184,000 unplanned hospital admissions that cost the NHS £434m to treat (2013/14). This is hardly surprising when we know that 20-30% of initial antibiotic prescribing for UTI fails (Chronic Urinary Tract Infection Campaign CUTIC).

The majority of these annual 15m diagnostic failures will relate to women, who with UTI, suffer the most pain, most time off work and loss of income, whilst being prescribed the highest rate of broad-spectrum antibiotics, putting us firmly in the front line of antibiotic immunity. The need for a robust protocol around urine analysis has become critical. Data from CUTIC tells us that:

  • 1.4m women suffer from chronic bladder pain and urinary dysfunction
  • 1 in 3 women will have a UTI by the age of 24
  • 50% of dipstick tests don’t detect infection
  • 70% of infections risk recurrence within a year
  • 47% of Gram-negative blood infections have a urinary source and can lead to potentially fatal sepsis

NHS Improvement advises that 50% of the global rise in Antimicrobial Resistance (AMR) has a urinary cause; yet our health service still routinely relies on unreliable dipstick tests to indicate infection, leading to broad spectrum antibiotics remaining the first prescribing port of call; for the pregnant woman this is highly undesirable as it can extend life-long risk of antibiotic immunity to the unborn child.

Overuse of antibiotics is directly linked to the lack of a protocol for urine collection, transportation and analysis. National contamination rates are as high as 70% in some areas of the country, a postcode lottery situation that fails patients, microbiologists and the clinicians whose job it is to make people better. Non-invasive and cheap to collect, urine can help diagnose myriad conditions that cost the NHS billions of pounds. They include:

  • Kidney stones, infection and disease
  • Bladder cancer
  • Diabetes mellitus
  • Hypertension
  • Liver disease
  • Pre-eclampsia and other potentially serious pregnancy related conditions

Matt Hancock, Secretary of State for Health and Professor Tim Briggs, founding father of the Department of Health’s NHS Getting It Right First Time programme (GIRFT) both cite the need to eliminate variation in national diagnosis and treatment. We must challenge them to make the changes necessary to this most basic diagnostic process, to save lives, save money and create a solid foundation upon which the evolution of diagnostic medicine can flourish.

Right now, the best digital diagnostic technology in the world that relies on urine, won’t work. If the basics are right, the rest can follow. If they are not, then Mr Hancock and Professor Briggs … keep on flushing.

Urine specimen testing

Urine Is Liquid Gold When It Comes To Testing

Today’s Hippocratic Post features an overview on the importance of urine and the evidence supporting why our technology plays such a vital role in enabling right-first-time diagnosis and treatment.

 

Giovanna Forte What is Peezy Midstream

Maximising our MedTech Might

The benefits of working with the NIHR are clearly demonstrated through past posts and this is the latest to come out of Forte Medical NIHR partnership…

“CEO of Forte Medical, describes how the NIHR supported her company to generate clinical evidence for the Peezy™ Mid-Stream Urine device – an easier, cleaner and more reliable urine sample collection. Watch the full video here: https://lnkd.in/gY-6MMx

Or get in touch: supportmystudy@nihr.ac.uk

Forte Medical Peezy Midstream on TV

Case Study – NIHR Support

A little while ago, the NIHR supported Forte Medical Ltd on a usability study for the Peezy™ Mid-Stream Urine device – an easier, cleaner and more reliable urine sample collection.   This is the interview filmed with Giovanna Forte last week.

 

The study: https://www.nihr.ac.uk/life-sciences-industry/access-to-expertise-and-collaborations/work-with-leading-academic-and-clinical-research-experts/nihr-medtech-services/medtech-case-studies/forte-medical.htm

 

Misdiagnosis of urine samples

Mr Ased Ali – Making Urine Samples Trustworthy

The latest issue of Urology News features an interesting and important conversation with Urological Consultant Mr Ased Ali about the importance of urine in diagnosis and subsequent treatment of UTIs.  He refers to the patient-led initiative – the MUST Campaign – that is demanding Government introduce a protocol for the collection of urine specimens.

The article supports the work being undertaken – the petition can be signed here – and the article itself is on page 35 of the November/December issue.

Clinical research using the Peezy Midstream shows a 70% reduction in false positive dipped urines and mixed growth/contamination reduced from the national average of 22.5% to just 2%.  Our contribution to making urine samples trustworthy

Peezy Usability Study Forte Medical

Peezy Midstream Case Study at NHS NIHR Conference 2018

Back in March of this year, the NHS National Institute for Health Research contacted Forte Medical, asking for a case study demonstrating how their research has assisted the launch of Peezy Midstream.

A few months earlier the NIHR in conjunction with the West Midlands AHSN conducted a valuable Usability Study on our diagnostic device. Results were excellent and have assisted us with adoption training and reassurance to HCPs and patients alike that using Peezy Midstream is far, far easier than trying to deliver this elusive urine specimen any other way …

The case study presented by Giovanna Forte on 10th October 2018 was very well received and has already led to enquiries from Primary Care clinicians who can see the benefit of right-first-time diagnoses for UTI and other common conditions that can take up so much GP time when left untreated.

2018 NIHR Peezy Presentation

NIHR_PeezyMidstream-Case-Study